ElectroCore's Non-invasive Nerve Stimulator Effective Against Migraine

ElectroCore Inc (NASDAQ: ECOR) announced the publication of a peer-reviewed paper entitled "Non-invasive vagus nerve stimulation (nVNS) for the prevention of migraine" in Cephalalgia, the official journal of the International Headache Society.

• The paper reports the results of a randomized, double-blind, sham-controlled trial of gammaCore. 
•  Originally designed to randomize 400 patients, the study was closed early due to COVID-19 after enrolling 231 subjects.
• Related: ElectroCore Stock Is Trading Higher As Ladenburg Initiates Coverage With $3 Price Target, Buy Rating.
• gammaCore is a non-invasive, hand-held medical therapy applied at the neck as adjunctive therapy to treat migraine and cluster headache by utilizing a mild electrical stimulation to the vagus nerve that passes through the skin. 
• The study results showed a decrease in the number of monthly headache days of 4.6 vs. -3.0 for sham (p=0.05).
• 44.87% of subjects in the gammaCore group had more than a 50% reduction in migraine days per month compared with 26.81% for the sham group (p=0.05). 
• Quality of life improved by -4.9 points vs. -2.3 for sham (p<0.05). 
• In the subpopulation of patients diagnosed with migraine with aura, the number of headache days decreased by 5.5 days in the nVNS group compared with 2.7 in the sham group (p=0<0.05), a therapeutic gain of >100% compared to sham. 
• Price Action: ECOR shares closed 4.21% higher at $0.56 during after-hours trading on Monday.